Shares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full ...

Shares Biotechnology ETF earns a reiterated hold rating as it consolidates near all-time highs with balanced risk/reward.

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Quick Read Direxion Biotech Bull 3X (LABU) doubled over the past year by delivering three times the daily biotech index return. FDA drug approvals often trigger 20% to 50% single-day stock jumps that ...

This was a new position; the IBB stake now accounts for 8.7% of Florin Court Capital LLP’s 13F AUM ICLN: $16.6 million (13.0% of AUM) IBB: $11.1 million (8.7% of AUM) IVW: $11.0 million (8.6% of AUM) ...

Our senior market strategist explains which ETFs offer exposure to high-powered biotech growth, without T. Rex-sized risk.

Virtus LifeSci Biotech Clinical Trials ETF BBC is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 138.3% from its 52-week low price of $13.42/share.

For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week ...

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ...

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...